Imbria – Optimizing cellular energy to treat cardiometabolic disorders

New treatments to enhance or restore how cells produce energy

At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.

Developing new treatments for cardiometabolic disorders

Non-obstructive hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence in the general population of 1:200.

Stable angina

Chest pain from angina can feel like a heart attack. Stable angina affects more than 4% of the adult population and leads to significant reduction in quality of life.

Heart failure with preserved ejection fraction

Heart failure is a clinical syndrome characterized by the inability of the heart to sufficiently pump blood to meet the body’s metabolic needs.

Latest news

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

January 09, 2023

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

December 05, 2022

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy